PRF Technologies (PRFX) Liabilities and Shareholders Equity (2019 - 2025)

PRF Technologies (PRFX) posted quarterly Liabilities and Shareholders Equity of $12.0 million for Q4 2025, up 165.15% year-on-year from $4.5 million in Q4 2024, and up 7.49% on a QoQ basis from $11.2 million in Q2 2025.

PRF Technologies (PRFX) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends

PRF Technologies (PRFX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $12.0 million the latest figure, recorded in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 165.15% year-over-year to $12.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.8 million (up 129.96% YoY) and the FY2025 annual result came in at $12.0 million, up 165.15% from the prior year.
  • Liabilities and Shareholders Equity climbed to $12.0 million in Q4 2025 per PRFX's latest filing, from $11.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for PRFX reached as high as $21.4 million in Q1 2021 and fell as low as $389000.0 in Q4 2023.
  • A 5-year average of $12.2 million and a median of $12.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 2267.3% — and 2023, when it sank 96.84%.
  • Year by year, Liabilities and Shareholders Equity stood at $19.1 million in 2021, then slumped by 35.36% to $12.3 million in 2022, then plunged by 96.84% to $389000.0 in 2023, then soared by 1063.24% to $4.5 million in 2024, then surged by 165.15% to $12.0 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $12.0 million, $11.2 million, and $4.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 PRF Technologies 745,168.93 451,168.93 - 12.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 12.00 Mn
Jun 30, 2025 11.16 Mn
Dec 31, 2024 4.53 Mn
Jun 30, 2024 3.11 Mn
Mar 31, 2024 5.37 Mn
Dec 31, 2023 389,000.00
Sep 30, 2023 10.89 Mn
Jun 30, 2023 8.32 Mn
Mar 31, 2023 10.42 Mn
Dec 31, 2022 12.33 Mn
Sep 30, 2022 14.85 Mn
Jun 30, 2022 15.99 Mn
Mar 31, 2022 17.71 Mn
Dec 31, 2021 19.07 Mn
Sep 30, 2021 20.34 Mn
Jun 30, 2021 19.84 Mn
Mar 31, 2021 21.35 Mn
Dec 31, 2020 17.80 Mn
Jun 30, 2020 838,000.00
Dec 31, 2019 1.16 Mn